BioSpace News Archive

According to Nova one advisor, the global Transplant Drug Monitoring Assay market size is expected to hit around USD 645.8 million by 2030 from valued at USD 200.4 million in 2021 and growing at a CAGR of 11.17% from 2022 to 2030.

According to Nova one advisor, the global Orthobiologics market was valued at USD 5.11 billion in 2021 and it is expected to hit around USD 7.18 billion by 2030 with a CAGR of 4.10% during the forecast period 2022 to 2030.

Eli Lilly and Company (NYSE: LLY) will begin rollout of its first connected platform, the Tempo® Personalized Diabetes Management Platform, later this year in the U.S. The technology aims to help adults living with type 1 or type 2 diabetes and clinicians make informed, data-backed decisions to manage treatment with Lilly insulins.

Insightec announced the publication of the largest prospective, long-term follow-up study of unilateral MRI-guided focused ultrasound thalamotomy for essential tremor to date.

MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM dedicated to improving survival outcomes for patients with cancer, announced the company’s scientific and management team’s participation in several scientific and investor conferences in November.

EdiGene, Inc. announced its subsidiary, EdiGene Biotechnology USA, has moved into a new Research & Development Center in Waltham, Mass.

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided an EU regulatory update for AT-GAA.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it will participate in the Guggenheim 4th Annual Immunology and Neurology Day, November 14th and 15th.

Mirum Pharmaceuticals, Inc., presented new data from LIVMARLI® oral solution studies, including two late-breaker presentations, at The Liver Meeting® of the American Association for the Study of Liver Diseases taking place November 4-7, 2022 in Washington, D.C.

Aleta Biotherapeutics, a privately held immuno-oncology company with novel biologic CAR T engagers that work in synergy with cell therapies to improve outcomes for patients, announces that the U.K.